Cytogenetic and teratogenic evaluation of letimide.
Letimide is a new efficient analgesic salicylate derivative. In this study we evaluated its cytogenetic and teratogenic potential. For chromosomal aberrations and sister chromatid exchange analysis we tested 250, 375, 500 and 625 micrograms/ml of letimide in human lymphocyte cultures in vitro, and for the in vivo cytogenetic study analysing the same parameters we studied the effects of 30, 50 and 100 mg/kg in mouse bone marrow cells. The teratogenic study was performed at dosages of 50, 100 and 200 mg/kg/d of letimide in mice. The results agree with the systems studied previously, showing no significant effect in the rate of aberrations, sister chromatid exchanges or congenital malformations induced by this new analgesic.
Díaz Barriga-Arceo
S
S
Departamento Morfología, Escuela Nacional de Ciencias Biológicas, Mexico, D.F.
Madrigal-Bujaidar
E
E
Salazar
M
M
Chamorro
G
G
D000328:Adult; D000700:Analgesics / Q000633:toxicity; D000818:Animals; D002478:Cells, Cultured; D002869:Chromosome Aberrations / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D008297:Male; D051379:Mice; D008938:Mitosis / Q000187:drug effects; D010078:Oxazines / Q000633:toxicity*; D011247:Pregnancy; D012854:Sister Chromatid Exchange; D013723:Teratogens / Q000633:toxicity*
D000700:Analgesics; D010078:Oxazines; D013723:Teratogens; C068350:letimide